Radioactive iodine, thyroid cancer

Portal Forums Q&A, Ask Us New Questions Radioactive iodine, thyroid cancer

This topic contains 3 replies, has 3 voices, and was last updated by JimC Forum Moderator JimC Forum Moderator 3 weeks ago.

Viewing 4 posts - 1 through 4 (of 4 total)
Author Posts   
Author Posts
September 3, 2017 at 7:59 am  #1291379    


Can the stable iodine content, as well as the radioactivity per atom of RAI, within a given dose of RAI vary? If so, would these two variations affect the rate of success of a given diagnostic/therapeutic dose?

September 3, 2017 at 10:58 am  #1291383    
catdander forum moderator
catdander forum moderator

Hi dpanjwan,

I’m sorry but I’m not able to comment on your question. We don’t have specific information on thyroid cancer which is the type of cancer radioactive iodine therapy is used to treat.

I hope you get the answers you need.
All best,

September 3, 2017 at 11:56 am  #1291384    


Thank you for your quick response, Janine! Is it possible for GRACE to send this question to a Nuclear Medicine expert on Thyroid Cancer for an answer?

September 4, 2017 at 8:54 am  #1291398    
JimC Forum Moderator
JimC Forum Moderator

Hi dpanjwan,

I’m sorry, but at present we do not have an expert on thyroid cancer available to respond to your questions.

From my limited research, the rate of decay of each atom of any radioactive isotope, including the I-131 used in RAI, varies to a certain extent (one that cannot be specifically determined for each atom), but that the half-life of a given isotope is stated as the average decay rate of the many atoms used in treatment. In addition, the dose of RAI can vary significantly from one facility to another, and from one patient to another (for specific reasons as determined by the radiation oncologist). The dosage used would likely have a much greater effect on the efficacy of treatment in any particular case. With that in mind, it might be good to direct your questions to your own medical team to learn what specific factors, if any, were used to determine your dosage.

Forum moderator

Jul 2008 Wife Liz (51/never smoker) Dx Stage IV NSCLC EGFR exon 19
4 cycles Carbo/alimta, 65% shrinkage
Tarceva maintenance
Mar 2010 progression, added Alimta, stable
Sep 2010 multiple brain mets, WBR
Oct 2010 large pericardial effusion, tamponade
Jan 2011 progression, start abraxane
Jun 2011-New liver, brain mets, add Tarceva
Oct 2011-Dx Leptomeningeal carcinomatosis; pulsed Tarceva
At rest Nov 4 2011
Since then:

Viewing 4 posts - 1 through 4 (of 4 total)

You must be logged in to reply to this topic.